Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals who voluntarily decide to participate in this study and provide written informed consent~   * Healthy male and female adult at the age of 19 to 50 years (Part A)~  * Healthy male and female adult at the age of 19 to 75 years (Part B)~2. Individuals who are available for all visit procedures including telephone visits during the study period~Exclusion Criteria:~1. COVID-19 positive based on RT-PCR using upper respiratory tract or lower respiratory tract sampling or COVID-19 antibody positive~2. History of SARS-CoV, MERS-CoV or SARS-CoV-2 infection~3. History of vaccination against SARS-CoV, MERS-CoV or SARS-CoV-2~4. Immune system disorders including immunodeficiency disease~5. Clinically significant abnormalities in clinical laboratory test, ECGs and chest X-ray during screening in the opinion of the investigator~6. Fever within 3 days prior to screening or serious acute or chronic infection within 7 days prior to screening requiring systemic antibiotics or antivirals~7. Evidence or history of serious acute, chronic, or progressive disease which, in the opinion of the investigator, makes the individual ineligible for the study~8. History of severe allergic reactions or severe hypersensitivity reactions to the IP or any of its components~9. History of therapy that might affect immunity: treatment with immunosuppresants or immune modifying drugs, anticancer therapy, or radiotherapy within 3 months prior to screening~10. Women of childbearing potential who do not agree to use medically allowed methods of contraception or to be heterosexually inactive until 60 days after the last dose of the IP~11. Pregnant or breastfeeding woman~12. Treatment with other IPs within 6 months prior to participation in this study~13. Other reasons including medical reasons based on which the individual is considered to be ineligible for this study in the opinion of the investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Phase 1 - EuCorVac-19 Low dose group (Type: EXPERIMENTAL): Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
- Phase 1 - EuCorVac-19 High dose group (Type: EXPERIMENTAL): Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
- Phase 2 - EuCorVac-19 Low dose group (Type: EXPERIMENTAL): Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
- Phase 2 - EuCorVac-19 High dose group (Type: EXPERIMENTAL): Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
- Phase 2 - Placebo comparator group (Type: ACTIVE_COMPARATOR): Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval

Based on this trial design, predict the completion outcome and termination type (if applicable).